IPM Take
Type 1 diabetes is usually discussed through the lens of glucose, insulin and technology. But for many patients, the long-term threat is kidney and cardiovascular damage. FDA Priority Review for finerenone matters because it puts chronic kidney disease in type 1 diabetes into a new regulatory lane. The key issue is not only whether the medicine is approved. It is whether health systems can identify eligible patients through kidney biomarkers, monitor potassium and kidney function safely, and avoid turning a potential breakthrough into another access gap.
Executive Summary
The U.S. Food and Drug Administration has accepted Bayer’s supplemental New Drug Application and granted Priority Review for finerenone for adults with chronic kidney disease associated with type 1 diabetes. Finerenone, marketed as Kerendia, is a non-steroidal mineralocorticoid receptor antagonist already approved in the United States for chronic kidney disease associated with type 2 diabetes and for certain adults with heart failure. The new application is supported by the Phase III FINE-ONE trial, which showed a 25% reduction in urine albumin-to-creatinine ratio over six months compared with placebo in adults with type 1 diabetes and chronic kidney disease. If approved, Bayer says finerenone could become the first new treatment option in more than 30 years for adults with chronic kidney disease associated with type 1 diabetes.
Why it matters
- Regulators: The review will test how far kidney biomarker evidence, especially albuminuria reduction, can support expansion into a high-need type 1 diabetes population.
- Clinicians: Could offer a new treatment pathway for adults with type 1 diabetes and chronic kidney disease, a group with limited kidney-protective options beyond standard care.
- Payers: Reimbursement decisions will need to define eligibility, biomarker thresholds, monitoring requirements and added value compared with existing standard care.
- Patients: May eventually provide a new option to reduce kidney damage risk in a population where chronic kidney disease remains a major driver of kidney failure and cardiovascular events.
- Health systems: Would require systematic testing for albuminuria, kidney function monitoring, potassium monitoring and coordination between diabetes, nephrology, cardiology and primary care.
Type 1 diabetes is often treated as a glucose story.
That is only part of the picture.
For many people living with type 1 diabetes, the long-term danger is not only blood sugar. It is what years of disease can do to the kidneys, heart and blood vessels.
That is why FDA Priority Review for finerenone matters.
On 21 May 2026, Bayer announced that the U.S. Food and Drug Administration had accepted a supplemental New Drug Application and granted Priority Review for finerenone in adults with chronic kidney disease associated with type 1 diabetes.
Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It works by blocking mineralocorticoid receptor overactivation, a pathway linked to inflammation and fibrosis in the kidneys and cardiovascular system.
The drug is already approved for chronic kidney disease associated with type 2 diabetes. The new regulatory question is whether it should also move into type 1 diabetes, where kidney-protective treatment options remain limited.
The application is based on the Phase III FINE-ONE trial.
FINE-ONE evaluated finerenone in adults with type 1 diabetes and chronic kidney disease. The study used urine albumin-to-creatinine ratio, known as UACR, as its primary endpoint. UACR is a measure of albumin in the urine and is widely used as a marker of kidney damage and risk of disease progression.
In the trial, finerenone reduced UACR by 25% over six months compared with placebo, on top of standard care.
That result is clinically important, but it also raises a policy question.
This is not a simple “new drug works” story. It is a biomarker story.
The regulatory case relies heavily on albuminuria reduction as a marker linked to longer-term kidney and cardiovascular outcomes. Bayer also points to previous Phase III data in chronic kidney disease associated with type 2 diabetes, where reductions in albuminuria helped explain much of finerenone’s kidney benefit.
For personalised medicine, that is the interesting part.
The future of cardiometabolic care may not be organised only around diagnosis labels such as type 1 diabetes or type 2 diabetes. It may increasingly depend on measurable risk signals: albuminuria, estimated glomerular filtration rate, potassium levels, cardiovascular risk and disease progression.
That shift could help identify patients earlier and treat risk before kidney failure develops.
But it also creates a readiness test.
If finerenone is approved for this new use, health systems will need to know who qualifies. That means routine UACR testing, kidney function assessment and clear referral rules. It also means monitoring for hyperkalaemia, because mineralocorticoid receptor antagonists can increase potassium levels.
The treatment pathway will not sit neatly in one specialty.
Diabetologists may identify the patient. Nephrologists may manage kidney risk. Cardiologists may be involved because chronic kidney disease sharply increases cardiovascular risk. Primary care will often carry the long-term monitoring burden. Pharmacists may play a key role in medication review, adherence and safety.
That is where access could split.
Patients already connected to specialist diabetes and kidney care may benefit first. Patients with irregular monitoring, fragmented care or limited access to nephrology may be left behind, even if they are at high risk.
The FDA review therefore signals something bigger than a possible new indication.
It shows that cardiometabolic medicine is becoming more stratified, more biomarker-driven and more dependent on system readiness.
For type 1 diabetes, that could be a major step forward.
But approval alone will not protect kidneys.
Testing, referral, reimbursement and monitoring will decide whether the promise reaches patients.
